Claims for Patent: 8,518,406
✉ Email this page to a colleague
Summary for Patent: 8,518,406
Title: | Antibodies directed against pyroglutamate monocyte chemoattractant protein-1 (MCP-1 N1pE) |
Abstract: | Monoclonal antibodies which bind specifically to the proinflammatory cytokine pyroglutamate MCP-1 (MCP-1 N1pE) are described. |
Inventor(s): | Cynis; Holger (Halle/Saale, DE), Demuth; Hans-Ulrich (Halle/Saale, DE), Rahfeld; Jens-Ulrich (Lieskau, DE), Gans; Kathrin (Halle/Saale, DE), Schilling; Stephan (Halle/Saale, DE), Kampfer; Sonja (Germering, DE) |
Assignee: | Probiodrug AG (Halle-Saale, DE) |
Application Number: | 12/544,319 |
Patent Claims: | 1. An antibody or an antigen binding fragment thereof, that selectively binds to a pyroglutamate-carrying amino terminus of MCP-1 N1 pE, wherein the antibody or the antigen
binding fragment has substantially no cross-reactivity with an epitope other than the pyroglutamate-carrying amino terminus of MCP-1N1pE.
2. The antibody of claim 1, wherein said antibody is a monoclonal antibody. 3. The antibody of claim 1, wherein said antibody is a chimeric antibody. 4. The antibody to claim 1, wherein a variable part of a light chain of said antibody is encoded by the nucleotide sequence of SEQ ID NO: 33 and has the amino acid sequence of SEQ ID NO: 34, and wherein the variable part of the heavy chain of said antibody is encoded by the nucleotide sequence of SEQ ID NO: 35, and has the amino acid sequence of SEQ ID NO: 36. 5. The antibody according to claim 1, wherein a variable part of a light chain of said antibody is encoded by a nucleotide sequence of SEQ ID NO: 37 and has the amino acid sequence of SEQ ID NO: 38, and wherein a variable part of a heavy chain of said antibody is encoded by a nucleotide sequence of SEQ ID NO: 39, and has the amino acid sequence of SEQ ID NO: 40. 6. The antibody according to claim 1, wherein a variable part of a light chain of said antibody is encoded by a nucleotide sequence of SEQ ID NO: 41 and has the amino acid sequence of SEQ ID NO: 42, and wherein a variable part of a heavy chain of said antibody is encoded by a nucleotide sequence of SEQ ID NO: 43, and has the amino acid sequence of SEQ ID NO: 44. 7. The antibody according to claim 1, which is produced by hybridoma cells, wherein said hybridoma cells are selected from the group consisting of hybridoma cells deposited with the Deutsche Sammlung fur Mikroorganismen and Zellkulturen GmbH, DSMZ as DSM ACC 2905, DSM ACC 2906, DSM ACC 2907 and DSM ACC 2908. 8. The antibody according to claim 1, wherein said antibody is a humanized antibody. 9. The antibody according to claim 1, wherein said antibody is an antibody fragment, which retains a high affinity for MCP-1 N1 pE. 10. The antibody according to claim 1, or an antigen binding fragment thereof, wherein the antibody specificity for MCP-1 N1pE is sufficient for detection of MCP-1 N1 pE or variants thereof in a mammal. 11. The antibody according to claim 10, wherein said mammal is a rat, mouse or a human. 12. The antibody according to claim 1, which is a diabody or a single chain antibody which retains a high affinity to MCP-1 N1 pE. 13. The antibody according to claim 1, wherein complementarity determining regions of the antibodies comprise a complementarity determining region of an antibody produced by hybridoma cells selected from the group consisting of hybridoma cells deposited with the Deutsche Sammlung fur Mikroorganismen und Zellkulturen GmbH, DSMZ as DSM ACC 2905, DSM ACC 2906, DSM ACC 2907 and DSM ACC 2908. 14. The antibody according to claim 1, which is labeled. 15. The antibody according to claim 1, which is immobilized on a solid phase. 16. A composition, comprising the antibody or an antigen binding fragment of claim 1. 17. A composition comprising the antibody of claim 1, or an antigen binding fragment thereof and, optionally, at least one of a further biologically active substance, a pharmaceutically acceptable carrier, a diluent, or an excipient. 18. The composition of claim 17, wherein said further biologically active compound is selected from the group consisting of neuron-transmission enhancers, psychotherapeutic drugs, acetylcholine esterase inhibitors, calcium-channel blockers, biogenic amines, benzodiazepine tranquillizers, acetylcholine synthesis, storage or release enhancers, acetylcholine postsynaptic receptor agonists, monoamine oxidase-A or -B inhibitors, N-methyl- D-aspartate glutamate receptor antagonists, non-steroidal anti-inflammatory drugs, antioxidants, serotonergic receptor antagonists, CCR2 receptor antagonists and MCP-1 antibodies. 19. The composition of claim 17, wherein said further biologically active compound is selected from the group consisting of a compound effective against oxidative stress, anti-apoptotic compounds, metal chelators, inhibitors of DNA repair .alpha.-secretase activators, tau proteins, neurotransmitter, .beta.-sheet breakers, attractants for amyloid beta clearing/depleting cellular components, inhibitors of N-terminal truncated amyloid beta peptides including pyroglutamated amyloid beta 3-42, inhibitors of glutaminyl cyclase, anti-inflammatory molecules, cholinesterase inhibitors (ChEls), an amyloid or tau modifying drug, and nutritive supplements. 20. The composition of claim 19, wherein said further biologically active compound is a cholinesterase inhibitor (ChEI). 21. The composition of claim 20, wherein said cholinesterase inhibitor is selected from the group consisting of tacrine, rivastigmine, donepezil, galantamine, niacin and memantine. 22. The composition of claim 19, wherein said further biologically active compound is a glutaminyl cyclase inhibitor. 23. The pharmaceutical composition of claim 22, wherein said glutaminyl cyclase inhibitor is 1-(3-(1H-imidazol-1-yl)propyl)-3-(3,4-dimethoxyphenyl)thiourea-hydrochlor- ide. 24. The composition of claim 17, wherein said further biologically active compound is selected from PEP-inhibitors, LiCI, inhibitors of DP IV or DP IV-like enzymes; acetylcholinesterase (AChE) inhibitors, PIMT enhancers, inhibitors of beta secretases, inhibitors of gamma secretases, inhibitors of neutral endopeptidase, inhibitors of phosphodiesterase-4, TNFalpha inhibitors, muscarinic M1 receptor antagonists, NMDA receptor antagonists, sigma-1 receptor inhibitors, histamine H3 antagonists, immunomodulatory agents, immunosuppressive agents or an agent selected from antegren (natalizumab), Neurelan (fampridine-SR), campath (alemtuzumab), IR 208, NBI 5788/MSP 771 (tiplimotide), paclitaxel, Anergix.MS (AG 284), SH636, Differin (CD 271, adapalene), BAY 361677 (interleukin-4), matrix-metalloproteinase-inhibitors (e.g. BB 76163), interferon-tau (trophoblastin) and SAIK-MS; beta-amyloid antibodies, cysteine protease inhibitors; MCP-1 antagonists, amyloid protein deposition inhibitors and beta amyloid synthesis inhibitors. 25. A method of producing an antibody that selectively binds to MCP-1 N1pE comprising: culturing a hybridoma cell selected from the group consisting of hybridoma cells deposited with the Deutsche Sammlung fur Mikroorganismen and Zellkulturen GmbH, DSMZ as DSM ACC 2905, DSM ACC 2906, DSM ACC 2907 and DSM ACC 2908; and isolating an antibody, or an antigen binding fragment thereof, of claim 1. 26. A hybridoma cell line selected from the group consisting of DSM ACC 2905, DSM ACC 2906, DSM ACC 2907 and DSM ACC 2908, all deposited with the Deutsche Sammlung fur Mikroorganismen und Zellkulturen GmbH, DSMZ. |
Details for Patent 8,518,406
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Jubilant Hollisterstier Llc | N/A | positive skin test control-histamine | Injection | 103891 | 03/13/1924 | ⤷ Try a Trial | 2028-08-20 |
Genzyme Corporation | CAMPATH | alemtuzumab | Injection | 103948 | 05/07/2001 | ⤷ Try a Trial | 2028-08-20 |
Genzyme Corporation | LEMTRADA | alemtuzumab | Injection | 103948 | 11/14/2014 | ⤷ Try a Trial | 2028-08-20 |
Genzyme Corporation | CAMPATH | alemtuzumab | Injection | 103948 | 10/12/2004 | ⤷ Try a Trial | 2028-08-20 |
Biogen Inc. | TYSABRI | natalizumab | Injection | 125104 | 11/23/2004 | ⤷ Try a Trial | 2028-08-20 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.